• Opportunity
• Competitive Advantage
• Accomplishments

Accomplishments

From the very beginning, MacuCLEAR’s prize-winning business plan has been intended as a strategic overview for the direction of the company’s growth and technology development. Nonetheless, it is also intended to be a dynamic document, updated and adjusted to reflect actual events. Here are some of our accomplishments since our Company’s founding in the fall of 2006:

• MacuCLEAR completed its initial, series A preferred stock funding on April 17, 2007, exceeding the business plan objective for funding. Investors constitute private investor groups from Dallas and Austin, Texas.
• MacuCLEAR completed its board of directors with five members, including CEO Phil Ralston; CSO Dr. George Chiou; Vice Chancellor for Technology Transfer from Texas A&M, Guy Diedrich; the lead investor, David Nelson, JD; and Dennis McWilliams, CEO, Apollo Endosurgery.
• MacuCLEAR entered into a sponsored research agreement, in June, 2007, with the Texas A&M Research Foundation for  $250,000 a year for the next two years to cover the pharmacodynamic work related to formulation development of our technology. This work conducted under the direction of Dr. George Chiou, the inventor of MC1101, has resulted in two effective dose forms and demonstrated efficacy in animal models to date..
• MacuCLEAR partnered with Pam Lewis and Associates, Inc., of Boerne, Texas in July 2007, to do preclinical formulation and stability work related to finalizing the topical formulation of MC1101 that is intended to be used in our human clinical program. This relationship has resulted in at least two formulations that show manufacturability and three-month stability so far. A two year, real-time stability study has been initiated to comply with anticipated FDA requirements. This work has been completed under budget and ahead of schedule.
• MacuCLEAR has completed a pre-IND meeting with the FDA producing positive results. It accomplished this goal on less than half of its initial funding and two months ahead of schedule. It expects to remain on schedule to be in human clinical trials before the end of 2008.
• MacuCLEAR has filed for PCT patent coverage in Europe, Canada, Australia and Japan. It has received a German Utility certificate in second quarter 2008. First office action from the U.S. Patent Office is expected spring 2008. MacuCLEAR’s freedom to operate and patentability have been reconfirmed with patent counsel in 2008.

Management believes MacuCLEAR is effectively following its business plan and accomplishing the strategic objectives laid out in the details that follow. We welcome any questions or comments.